Meet ALK+ advanced NSCLC head on with LORVIQUA

LORVIQUA has shown durable benefit, both in previously treated and treatment naïve, ALK+ advanced NSCLC patients with or without brain metastases.1,2,5

Consider LORVIQUA as a first-line option for patients with ALK+ advanced NSCLC with or without brain metastases at baseline1,2

  • LORVIQUA demonstrated a significant improvement in PFS vs crizotinib, in patients with or without brain metastases1
  • LORVIQUA was designed to cross the blood barrier and has shown improved intracranial activity, suggetsing a protective effect against brain metastases. 2,3,4,5
  • LORVIQUA has a generally manageable safety profile with largely mild-to-moderate adverse reactions.1,2
  • However grade 3 and 4 ADRs, including Hypercholesterolaemia and hypertriglyceridemia, mean that LORVIQUA is subject to additional monitoring.1,2,5


Indications
  • LORVIQUA as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.1
  • LORVIQUA as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:
    • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or
    • crizotinib and at least one other ALK TKl.1
LORVIQUA efficacy
 Discover the data Loading
LORVIQUA safety profile
 Review the safety Loading
Therapy management
  See the strategies LoadingALK=anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer; CNS=central nervous system; PFS=progression-free survival.ReferencesReferences:LORVIQUA  Summary of Product Characteristics. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654-1667.Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]­benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57(11):4720-4744.Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Solomon, Bauer et al. Lancet Respir Med 2023;11(4):354-366
 
  •  
  •  
  •  
PP-LOR-IRL-0093 February 2024 Legal Category S1A Further information available on request
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024